(Q80952728)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16051303%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

title

Characterization of antibody responses to purified HIV-1 gp120 glycoproteins fused with the molecular adjuvant C3d (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16051303%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

3

Joseph Sodroski

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16051303%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

4

Richard Wyatt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16051303%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

author name string

Markus Koch

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16051303%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

James Frazier

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16051303%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

publication date

1 September 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16051303%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

volume

340

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16051303%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16051303%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

277-284

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16051303%20AND%20SRC:MED&resulttype=core&format=json

CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1

4 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Regulated expression allows high level production and secretion of HIV-1 gp120 envelope glycoprotein in Drosophila Schneider cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

C3d of complement as a molecular adjuvant: bridging innate and acquired immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Identification of a major co-receptor for primary isolates of HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Cutting edge: C3d functions as a molecular adjuvant in the absence of CD21/35 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

LPS, TLR4 and infectious disease diversity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

The antigenic structure of the HIV gp120 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.06.034

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2005.06.034

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16051303%20AND%20SRC:MED&resulttype=core&format=json

4 January 2020

1 reference